Ophthalmology Advisor’s Post

#ARVO2024:Patients who receive long-term anti-glaucoma topical medication have approximately 3.5 times the risk of selective laser trabeculoplasty (SLT) failure, according to a poster presented at the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO), held in Seattle, May 5-9. Toby Al-Mugheiry, MD, and a research team of Ian Nunney, and David Broadway, from the Norfolk and Norwich University Hospitals NHS Foundation Trust in the United Kingdom presented the research, which explored the long-term impact of using topical antiglaucoma medications and what factors increase the risk of selective laser trabeculoplasty failure. Read here: https://brnw.ch/21wJQZS #Glaucoma #TopicalMedication #SelectiveTrabeculoplasty #SLT #SLTFailure #AntiGlaucomaMedications #Ophthalmology #Ophthalmologist #EyeCare

Low-level red-light (LLRL) therapy increases subfoveal choroidal thickness, which limits myopia progression and development among children with premyopia, according to a study published in the Asia Pacific Journal of Ophthalmology. Read here: https://bit.ly/4gv1Rbb #LowLevelRedLightTherapy #SubfovealChoroidalThickness #Myopia #MyopiaProgression #PreMyopia #Optometry #EyeCare #EyeHealth

#AAO2024: The uveitis burden may be higher in the United States than previously thought. Uveitis is associated with approximately a quarter of all cases of legal blindness, and the disease’s prevalence within the United States appears to be larger than earlier studies suggest, according to research presented at the American Academy of Ophthalmology, held in Chicago, October 18 to 21, 2024. Nila K., a Drexel University College of Medicine student, presented the research. The co-authors of the study were fellow Drexel University College of Medicine students Rayna Marshall and Matthew Spangler, and Drexel University College of Medicine alumna MEGHAN BERKENSTOCK, MD, who is an associate professor of ophthalmology at the Wilmer Eye Institute, Johns Hopkins Medicine. Read here: https://bit.ly/4dXldDM #Uveitis #UveitisBurden #LegalBlindness #Blindness #DiseasePrevalence #Ophthalmology #EyeHealth #EyeCare #EyeResearch #MedicalNews

In intermediate age-related macular degeneration (AMD), greater drusen height is associated with an increased risk for developing intraretinal hyper-reflective foci (IHRF), according to a study published in the Ophthalmology at BMJ. The study also shows that overlying ellipsoid zone (EZ) disruption substantially increases IHRF development risk, and that drusen further from the fovea reduced this risk. Read more: https://brnw.ch/21wIO6A #IntermediateAgeRelatedMacularDegeneration #Ophthalmology #EyeCare #AgeRelatedMacularDegeneration #IntraretinalHyperReflectiveFoci #IHRF

Individuals with an inter-eye variation in axial length and primary open-angle glaucoma (POAG) demonstrate faster and more severe glaucoma progression in the longer, more myopic eye, according to a retrospective investigation published in Ophthalmology (American Academy of Ophthalmology). Read more: https://bit.ly/4fS7IaA #InterEyeVariation #AxialLength #PrimaryOpenAngleGlaucoma #POAG #GlaucomaProgression #Glaucoma #Optometry #MyopicEye #EyeCare

In intermediate age-related macular degeneration (AMD), greater drusen height is associated with an increased risk for developing intraretinal hyper-reflective foci (IHRF), according to a study published in the Ophthalmology at BMJ. The study also shows that overlying ellipsoid zone (EZ) disruption substantially increases IHRF development risk, and that drusen further from the fovea reduced this risk. Read more: https://brnw.ch/21wICTj #IntermediateAgeRelatedMacularDegeneration #Ophthalmology #EyeCare #AgeRelatedMacularDegeneration #IntraretinalHyperReflectiveFoci #IHRF

Peripapillary retinal nerve fiber layer (RNFL) and ganglion cell inner plexiform layer (GCIPL) thicknesses show high diagnostic accuracies for detecting glaucoma in eyes with high axial myopia, according to research published in the American Journal of Ophthalmology. Read here: https://brnw.ch/21wKHj0 #PeripapillaryRetinalNerveFiberLayer #RetinalNerveFiberLayer #RNFL #GanglionCellInnerPlexiformLayer #GCIPL #Glaucoma #AxialMyopia #Optometry #EyeCare #EyeHealth #OCTParameters

An updated age-related macular degeneration severity scale reflects a higher rate of disease progression in patients with reticular pseudodrusen (RPD) than in those without, according to a publication printed in Ophthalmology (American Academy of Ophthalmology). The Age-Related Eye Disease Study (AREDS and AREDS2) research group also redesignated noncentral geographic atrophy (GA) as an outcome of age-related macular degeneration (AMD), rather than simply being a risk factor. Read more: https://brnw.ch/21wK74x #AgeRelatedMacularDegeneration #ReticularPseudodrusen #RPD #AREDS #AREDS2 #GeographicAtrophy #GA #Ophthalmology #EyeHealth #EyeCare

#JOJ Ophthalmology #A Mimicker of Haemangioma: A Case Report of Orbital Alveolar Soft Part Sarcoma Excised by Endoscopic Transorbital Approach in A 3-Year-Old Child and A Review of Literature #Abstract: Alveolar soft part sarcoma (ASPS) is a rare sarcoma arising from skeletal muscles or fascia favorably in lower extremities and trunks. It was reported that the most common site was extremities while 15% was found in head and neck region in two series of pediatric and adolescent ASPS. Pediatric ASPS may be misinterpreted as haemangioma or arteriovenous malformation by radiological investigations. Therefore, histopathological examination with immunopositivity of TFE3 is necessary for diagnosis of ASPS. We present the case of a 3-year-old girl diagnosed ASPS with surgical excision done by both neurosurgeons and ophthalmologists. A comprehensive literature review was performed to investigate the clinical characteristic of pediatric orbital ASPS, treatment modalities and clinical outcomes. #Alveolar Soft Part Sarcoma #Magnetic Resonance Imaging #Endoscopic Transcaruncular Approach #CT Imaging #Radiotherapy #https://lnkd.in/ewCGdJFV #https://lnkd.in/eMX8BUPz

#ARVO2024: An extended aflibercept dosing interval may be appropriate for patients with polypoidal choroidal vasculopathy (PCV), according to research presented at the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting held in Seattle, May 5 to 9, 2024. Patients with PCV appear to maintain similar improvements in best-corrected visual acuity (BCVA) when treated with aflibercept 8 mg monotherapy every 12 (8q12) or 16 weeks (8q16) compared with a dosing interval of 2 mg every 8 weeks (2q8), according to the presentation. Study authors included Rufino Silva, MD, (Universidade de Coimbra), Tien Yin Wong 黄天荫 (Singapore National Eye Centre, Tsinghua University School of Medicine), Gemmy Cheung (Singapore National Eye Centre, Duke-NUS Medical School), Jeff Heier (Ophthalmic Consultants of Boston), Won Ki Lee (Nune Eye Hospital), Tomohiro Iida (Tokyo Joshi Ika Daigaku), Xin Zhang, M.D., Ph.D. (Bayer Consumer Care AG), Tobias Machewitz (Bayer AG), Andrea Schulze (Bayer AG), and Sérgio Leal (Bayer Consumer Care AG). Read here: https://brnw.ch/21wJLud #Aflibercept #PolypoidalChoroidalVasculopathy #PCV #EyeCare #BestCorrectedVisualAcuity #Monotherapy #Ophthalmology #EyeHealth